NeuroMedics Technology Inc.
has been established as a vehicle
for the commercialization of EEG-driven light sound stimulation (EDLSS)
technology as treatment for attention deficit/hyperactivity disorder. . NeuroMedics has acquired license to
core technology patents
and related intellectual property from NeuroTrain LLC and Synetic Systems Inc.,
and upon funding intends to complete a large confirming clinical trial and thereafter
FDA premarket approval (PMA) for the treatment of ADHD. Please
us for further details.
Our management team concisely embodies the skillset required to execute
our business strategy.
Sorenson, Chairman, President, and Chief Executive Officer
Richard Sorenson is the President and CEO of the Company
and additionally serves on the board of directors of PointOne Telecommunications
and Broadband Networks. Mr.
Sorenson was the President and CEO of PointOne Telecommunications Inc., a
full-service voice and data communications company that he co-founded in 1998.
In June 2000 Mr. Sorenson recruited a telecom veteran from Sprint Corporation to
take over responsibilities as CEO.
A seasoned executive with 20 years in the high technology
and medical industries, Mr. Sorenson is highly experienced in executive
management, business development, mergers and acquisitions, corporate financial
management and operations, and sales and marketing. During his career prior to PointOne, he was with American
Hospital Supply for 7 years and the Intermedics’ companies for 11 years.
Specifically, the operations he was involved with were heavily oriented
towards pharmaceutical and bio-medical device research, development,
manufacturing, and sales.
Recognizing the opportunity in the communications market,
Mr. Sorenson was responsible for raising the necessary capital and building the
management team to launch PointOne. PointOne
is a full service voice and data solutions company, offering converged services
on a next-generation packet-based network.
Before founding PointOne, Mr. Sorenson enjoyed a
successful career at Intermedics, Inc., where he began as Director of Finance.
In that position, he contributed significantly to the turnaround of the
financially troubled company, developing and implementing planning process to
provide focus to operations. Later, he was a key member of the team responsible
for the marketing and sale of Intermedics to Sulzer Limited of Switzerland, for
Following the sale of Intermedics, Mr. Sorenson was named
Vice President of Finance for Sulzer Carbomedics, Inc. and Sulzer Vascutek,
Ltd., and later became Vice President for Business Development. While in that
position, he was a member of the international team responsible for the $40
million acquisition of Vascutek, a Scottish vascular graft sales, marketing, and
Prior to his career at Intermedics, Mr. Sorenson held
several positions of increasing responsibility at American Hospital Supply
Corporation from 1981 through late 1987 when he was recruited to Intermedics,
A native of Hinsdale, Illinois, Mr. Sorenson earned a
Bachelors of Science in Finance at the University of Colorado and a Masters in
Management at Northwestern University in Evanston, IL. He has done additional
coursework at Harvard University and is a CPA registered in the State of
Mr. Sorenson is active in charitable and civic
organizations, and. has served on the boards of the American Heart Association,
Seton Hospital, Paramount Theater and has led significant fundraising efforts
for those organizations, as well as the American Cancer Society, the Junior
League, and various school and church activities. Mr. Sorenson resides in Austin with his wife and two
Vice President, Clinical and Regulatory (Name
Provided on Confidential Basis)
A Vice President for Clinical and Regulatory
has been selected who will join the Company post-funding. The
individual’s information will be provided on a confidential basis in
order to protect his current employment.
The individual has highly relevant medical
device experience over a career of 20+ years in clinical and
regulatory and has had extensive experience in developing appropriate
systems to comply with the requirements of the United States Food and
Drug Administration and with other regulatory agencies around the
world. He also has extensive experience in supporting Marketing and
W. Daniel Vaughn
Vice President Administration, Director
Mr. Vaughn will join the Company in July 2002
upon departure from his current law firm, McLeod, Alexander, Powel, &
Apffel, p.c. Mr. Vaughn has served as legal counsel to the Company
since its inception. He is an officer/shareholder in the law firm of
McLeod, Alexander, Powel & Apffel, P.C., and has been with the firm
since 1977. He has represented a variety of businesses, governmental
and nonprofit entities, financial institutions and individual clients.
Mr. Vaughn earned his J.D. in 1975 from the
University of Texas at Austin and a B.A. in Government from the
University of Texas at Austin in 1972. Mr. Vaughn is currently
enrolled in the University of Houston Law Center LL.M. Program in
Intellectual Property Law.
Scientific Advisory Board
J. F. Wernicke, Ph.D., M.D.
Doctor of Medicine, University of
California, Irvine 1979
Ph.D. Biological Chemistry, University
of California, Los Angeles 1974
B.S., Biochemistry, Texas A&M
Wernicke has a highly relevant background and experience, creating an
unusual fit as an advisor for the Company. Dr. Wernicke’s experience
covers pharmaceutical and medical device companies focused on
neurological disorders, including ADHD, Depression, Parkinson’s
disease, and Epilepsy. Furthermore, with his specialty in neurology
and fellowship at Washington University in Child Neurology, Dr.
Wernicke is recognized as an expert in the areas specific to the
Wernicke is employed with Eli Lilly & Company in the clinical
development of atomoxetine for treatment of ADHD. Dr. Wernicke has
previously been instrumental in the clinical and regulatory
development of fluoxetine (Prosac®) and pergolide (Permax®), both
products approved by FDA. Dr. Wernicke’s involvement has included the
preparation and submission of NDA Supplements, direct negotiations
with FDA, design and implementation of extensive safety analysis
database, design and implementation of clinical development programs
and individual clinical trials for numerous compounds, and support of
international clinical trials and regulatory activities.
at Cyberonics, Dr. Wernicke was instrumental in the preparation
and submission of PMA for NeuroCybernetic Prosthesis (NCP®)
[implantable vagus nerve stimulator for treatment of refractory
epilepsy], design and implementation of multinational clinical trials
for devices using scientific approaches common to drug trials, direct
negotiations with FDA regarding submissions and approval process,
statistical analysis using SAS, and the management of clinical and
regulatory affairs group.
Dr. Wernicke is credited with 8
issued patents. Dr. Wernicke has published extensively in the areas
of neurological and psychiatric disorders.
L. Russell, Ph.D.
Ph.D., University of Houston, 1966, Clinical Psychology.
Dr. Russell is a semi-retired clinical
psychologist with a private practice in Galveston, Texas. Dr. Russell
is an adjunct research professor in the Department of Gerontology and
Health Promotion at The University of Texas Medical Branch at
Galveston. Prior to leaving full time work at UTMB to enter private
practice in 1979, Dr. Russell was an instructor and assistant
professor. Dr. Russell has had significant interest throughout his
professional career in psycho-neurological problems that are
considered difficult to treat. Dr. Russell has been extensively
involved in research and has published. Much of Dr. Russell's
published research has been in collaboration with Dr. Carter over a
number of years, including the groundbreaking research involving EDLSS
Ben G. Raimer, M.D.
Vice President for Community Outreach,
M.D. University of Texas Medical Branch
School of Medicine, 1974
Pediatric Residency Program at UTMB’s
Hospitals in 1977
MA, University of Texas Medical Branch,
1970, Human Genetics
East Texas Baptist College, 1969
American Board of Pediatrics Certified and
is a Fellow of the American Academy of Pediatrics
Dr. Raimer served as a community-based
pediatrician in Galveston County from 1977 until 1993, when he joined
UTMB as medical director for the Primary Care Outpatient Clinics. He
has served on the staff at Texas City Mainland Hospital, as chief of
staff at St Mary’s Hospital in Galveston, and as president of the
Galveston County Medical Society. In 1997, he became the chief
physician executive for UT-MED. Dr. Raimer continues to provide
medical care for children with learning and development disorders and
serves as professor of pediatrics and family medicine.
Dr. Raimer was appointed by Governor William P.
Clements to the Children’s Trust Fund of Texas and served an
eight-year term with the council. In 1997, Governor George W. Bush
appointed him chair of the Texas Statewide Health Coordinating
Council, which is charged with producing the State Health Plan. Dr.
Raimer was later appointed by Governor Bush to chair the Texas
Correctional Managed Health Care Committee.
In recognition of his work to prevent child
abuse, Raimer received the 1998 Ray Helfer Award on behalf of the
National Alliance of Children’s Trust and Prevention Funds and the
American Academy of Pediatrics Section on Child Abuse. He also
received UTMB’s Nicholas and Katherine Leone Award for Administrative
Excellence in 1998.
Ph.D., University of Texas at Austin, 1966, Educational Psychology and
Dr. Carter is a retired educational
psychologist and professor of education. During his thirty years at
the University of Houston, Dr. Carter received over 25 federal grants
and chaired 12 doctoral dissertations in his areas of specialty. Dr.
Carter received national recognition for some of his early studies on
the long lasting (ten year) effects of early educational
interventions. His findings were used as part of the support for the
establishment of the Head Start program. Dr. Carter has conducted and
participated in extensive research in the areas of brain function and
learning disabilities. Much of Dr. Carter's research has involved the
long-term effects of light and sound stimulation. Among the
groundbreaking research projects in which Dr. Carter was involved were
the studies of EDLSS technology in treating ADHD children funded by
Phase I and II Small Business Innovation Research grants through the
U. S. Department of Education. Dr. Carter has published extensively
and conducted many presentations prior to his retirement.
President, Synetic Systems Inc.
Mr. Austin obtained his A.S. in Chemical
Technology (SCCC, 1976) and continued his studies at the University of
Washington (1977-81). During the 1980's he developed several
microprocessor based computer music projects, and in 1987 began
developing the light and sound stimulation system he brought to market
in 1988, when he founded Synetic Systems Inc. During subsequent years
he has designed or overseen the design of numerous light and sound
stimulation systems, including three that utilized EEG measurements.
Consultants in Biomedical Research
SYNERGOS, Inc. is a Contract Research
Organization that provides comprehensive clinical research and
development services, from study design through regulatory
submission. SYNERGOS has substantial experience in pharmaceuticals,
medical devices, and biotechnology product development, with
significant expertise in numerous therapeutic and diagnostic areas.
To date, SYNERGOS has managed, analyzed, and produced reports for each
type of regulatory submission required by the FDA, including multiple
NDAs and PMAs. In particular, SYNERGOS has been involved in highly
relevant clinical and regulatory work for Medtronic’s Neurological
division and Cyberonics, Inc, Vagus Nerve Stimulation system.
SYNERGOS has provided strategic regulatory and clinical direction to
the Company and, post funding, the Company intends to engage SYNERGOS
to manage much of the clinical and regulatory aspects of the clinical
trials and regulatory submissions.
Copyright 2002 Neuromedics Technology Inc.